Cool.....unfortunately, nobody read the article to see they are trading at $32:00 and have $1.5 billion in revenue. A little different from where this company stands today. Not saying an orphan drug status approval won't send this into orbit, but lets use our heads a bit and be somewhat realistic.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.